Drug Discovery 2024

Excel, London, UK | 2 -3 October, 2024

Drug Discovery 2024

Connect with Abzena’s Robert Francis PhD at Drug Discovery 2024 and learn more about our latest developments in cell imaging at poster number 177 at the ELRIG conference https://elrig.org/portfolio/drug-discovery-2024/, 2nd – 3rd October.

Robert Francis - Abzena

‘Application of Real-Time Live Cell Imaging in the Development of Antibody-Drug Conjugates’

Learn from Robert on how Abzena provide live cell imaging expertise within our diverse range of offerings in developing and progressing your antibody-drug conjugate (ADC) and other complex biologics.

Abstract

Antibody-Drug Conjugates (ADCs) have rapidly become an important class of targeted therapeutics against cancer, delivering both the specificity of mAbs and the cytotoxicity of small molecule drugs. Continual developability assessment underpins all aspects of ADC drug discovery and development and the appropriate use of real- time live cell imaging as part of the developability assessment of ADCs can play a significant role in the selection of candidates with the greatest chance of clinical success.

To find out more, connect with Robert at Drug Discovery 2024 or visit our resources section after the event to download the poster.

Abzena is a biopharmaceutical CDMO & CRO that provides fully integrated, tailored drug design, development and manufacturing services spanning from early discovery through commercial.

Lets work together to move medicine forward.

Contact Us

About Robert Francis PhD

Robert is a Fellow of the Royal Microscopical Society (FRMS) and leads a bioassay team of scientists for live and fixed cell imaging within Abzena fulfilling contract research, including development of novel imaging based assays. Robert and his team play a key role in translating a scientific vision to practical step-by-step experimentation through scientific collaboration and consultation. Robert has over a decade of imaging experience and is based at our Cambridge, UK facility which specializes in early discovery services ahead of candidate selection for both complex biologics and bioconjugates.

Upcoming events